In this article, we discuss the top 5 stock picks of Paul Marshall and Ian Wace’s Marshall Wace LLP. If you want to read our detailed analysis of Marshall and Wace’s history, investment philosophy, and hedge fund performance, go directly to the Top 10 Stock Picks of Paul Marshall and Ian Wace’s Marshall Wace LLP.
5. Airbnb, Inc. (NASDAQ:ABNB)
Paul Marshall and Ian Wace’s Marshall Wace LLP’s Stake Value: $234,355,000
Percentage of Paul Marshall and Ian Wace’s Marshall Wace LLP’s 13F Portfolio: 0.97%
Number of Hedge Funds: 58
Airbnb, Inc. (NASDAQ:ABNB) is an online marketplace operator for lodging. Since its inception in 2017, Airbnb has expanded to 4 million hosts who have entertained over 1 billion guests. Paul Marshall and Ian Wace’s Marshall Wace LLP has a stake worth $234.4 million in the company as of Q3 2021.
In a note issued to investors on December 13, Kevin Kopelman at Cowen named Airbnb, Inc. (NASDAQ:ABNB) as the best idea for this year.
Tollymore Investment Partners discussed its stance on Airbnb, Inc. (NASDAQ:ABNB) in its Q3 2021 investor letter. Here’s what the investment management firm said:
“Today disruptors are not typically seeking to replace incumbents entirely. Rather, they break the links in the customer journey, in doing so better aligning monetisation with value creation and minimising externalities. For example, Airbnb broke the link between staying in residential property and owning it. Airbnb is a specific example of a business model innovation which separated asset use from ownership. This is hardly a novel idea; it’s called renting. Rental models lend themselves to assets which are expensive and durable, and where usage is infrequent.”
4. Teleflex Incorporated (NYSE:TFX)
Paul Marshall and Ian Wace’s Marshall Wace LLP’s Stake Value: $259,409,000
Percentage of Paul Marshall and Ian Wace’s Marshall Wace LLP’s 13F Portfolio: 1.07%
Number of Hedge Funds: 26
Teleflex Incorporated (NYSE:TFX) is a provider of specialized medical devices for the treatment of patients in critical care. The company operates in over 40 countries and employs more than 12,000 people.
On December 9, Shagun Singh at RBC Capital initiated coverage on Teleflex Incorporated (NYSE:TFX) with a $415 price target and an Outperform rating.
Teleflex Incorporated (NYSE:TFX) was mentioned in the Q1 2021 investor letter of ClearBridge Investments. Here’s what the investment management firm said:
“Teleflex is a diversified medical device company with leading market share in several low-cost consumable niche categories, creating high-margin recurring revenue streams with steady growth and pricing. Its unique UroLift product has the potential to accelerate growth of the company with its strong positioning as the only minimally invasive product to treat BPH in the prostate gland with no side effects, a treatment area with a large total addressable market.”
3. Microsoft Corporation (NASDAQ:MSFT)
Paul Marshall and Ian Wace’s Marshall Wace LLP’s Stake Value: $268,581,000
Percentage of Paul Marshall and Ian Wace’s Marshall Wace LLP’s 13F Portfolio: 1.11%
Number of Hedge Funds: 250
Microsoft Corporation (NASDAQ:MSFT) is the second-largest publicly traded company in the world and one of the three Big Five tech giants in Paul Marshall and Ian Wace’s Marshall Wace LLP’s portfolio. The Redmond, Washington-based company is involved in the production and marketing of operating systems, consumer electronic products, personal computers, software, etc.
Microsoft Corporation (NASDAQ:MSFT) was mentioned in the Q3 2021 investor letter of Baron Funds. Here’s what the firm said:
“Shares of Microsoft Corporation, a cloud-software leader and provider of software productivity tools and infrastructure, rose during the quarter following a strong earnings report highlighting solid demand for its broad product stack and continued momentum migrating its business to the cloud. Microsoft’s results continued to be strong across the board, with total revenue beating Street estimates by 4.5%, an acceleration in Commercial Cloud revenue to 31% constant-currency growth, a four-point improvement in Commercial Cloud gross margins (to 70% from 66%), and GAAP earnings up 42%. We believe the company is positioned to deliver 13% to 15% organic growth over the next three years, underpinned by TAM expansion across its disruptive cloud product portfolio, as more companies look to transform and digitize their businesses, as well as strong operating leverage as its cloud products gain scale.”
2. Bio-Rad Laboratories, Inc. (NYSE:BIO)
Paul Marshall and Ian Wace’s Marshall Wace LLP’s Stake Value: $327,728,000
Percentage of Paul Marshall and Ian Wace’s Marshall Wace LLP’s 13F Portfolio: 1.36%
Number of Hedge Funds: 38
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a Hercules, California-based corporation involved in the development, production, and marketing of clinical diagnostic products across the world. The life sciences tools and services entity operates through two segments, Clinical Diagnostics and Life Science.
Out of the 867 hedge funds being tracked by Insider Monkey, 38 funds reported owning a stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) at the end of Q3 2021. Marshall Wace LLP is the leading shareholder in the company, with a stake worth over $327.7 million as of Q3.
1. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Paul Marshall and Ian Wace’s Marshall Wace LLP’s Stake Value: $377,583,000
Percentage of Paul Marshall and Ian Wace’s Marshall Wace LLP’s 13F Portfolio: 1.56%
Number of Hedge Funds: 33
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is the New Haven, Connecticut-based biopharmaceutical corporation behind Rimegepant. The breakthrough therapeutic aids in the acute treatment of migraine and received FDA approval. The company is also working on developing the drug as a preventive treatment for migraine. Paul Marshall and Ian Wace’s Marshall Wace LLP initiated a significant position of over 2.5 million shares in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) in the third quarter of 2020.
On December 6, Christopher Raymond at Piper Sandler issued an Overweight rating on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock with a price target of $156.
You can also take a peek at the 10 Best Big Pharma Stocks to Buy Now and 11 Best Auto Stocks To Invest In.
